326 results on '"Ruet, Aurélie"'
Search Results
2. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course
3. Frequency and clinical relevance of MOG-antibodies in CSF in pediatric patients with MOG antibody-associated diseases
4. Gynaecological follow-up for women of reproductive age with multiple sclerosis: The GYNESEP study
5. A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica
6. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
7. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
8. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
9. Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort.
10. Frequency and clinical relevance of MOG-antibodies in CSF in pediatric patients with MOG antibody-associated diseases
11. Suivi gynécologique chez les patientes en âge de procréer atteintes de sclérose en plaques : étude GYNESEP
12. Évaluation de la couverture vaccinale des patients vivant avec une sclérose en plaques et suivis dans un centre hospitalier universitaire
13. Sclérose en plaques
14. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations
15. Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGADin Adults: The MOGADOR2 Study.
16. Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.
17. Cognitive assessment in patients with multiple sclerosis: From neuropsychological batteries to ecological tools
18. Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality
19. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
20. Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis.
21. Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
22. Preliminary evidence of the cerebellar role on cognitive performances in clinically isolated syndrome
23. Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions
24. Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study
25. Cognitive Impairment in Multiple Sclerosis
26. The radiologically isolated syndrome: revised diagnostic criteria
27. Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
28. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: a retrospective observational cohort study
29. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
30. Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease
31. Cerebellar Assessment in Early Multiple Sclerosis
32. Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
33. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France
34. Differential vulnerability of thalamic nuclei in multiple sclerosis
35. Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome
36. Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis
37. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
38. sj-docx-1-msj-10.1177_13524585221139156 – Supplemental material for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
39. sj-docx-1-msj-10.1177_13524585221101470 – Supplemental material for Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome
40. sj-docx-1-msj-10.1177_13524585221114247 – Supplemental material for Differential vulnerability of thalamic nuclei in multiple sclerosis
41. Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
42. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
43. Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease.
44. Differential vulnerability of thalamic nuclei in multiple sclerosis.
45. Cognitive Impairment in Multiple Sclerosis
46. Amygdala network reorganization mediates the theory of mind performances in multiple sclerosis
47. Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries
48. Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study
49. Do isolated cognitive relapses exist? Commentary
50. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.